PDA TR 63

Technical Report No. 63 (TR 63) Quality Requirements for the Extemporaneous Preparation of Clinical Trial Materials

Parenteral Drug Association , 09/01/2013

Publisher: PDA

File Format: PDF

$162.00$325.00


A recent benchmarking exercise conducted by the PDA Quality Requirements for the Extemporaneous Preparation of Clinical Trial Materials Technical Report Team indicates that extemporaneous preparation (EP) techniques are widely used to prepare a variety of formulations for a variety of dosage forms for small-scale clinical studies where dosing is in-clinic. Since the quality requirements for dose preparation activities that occur at clinical sites are not always clear, this gap becomes very important as investigators are increasingly using EP to support small-scale clinical studies. While traditional CGMP systems may not be in place in such areas, there still must be appropriate controls in place to ensure patient safety. Technical Report No. 63: Quality Requirements for the Extemporaneous Preparation of Clinical Trial Materials describes a quality system that will support the preparation of clinical trial materials in a nonmanufacturing environment in a manner that will ensure product quality and patient safety.

More PDA Standards PDF

PEI RP1300-20

PEI RP1300-20

$197.00 $395.00

PEI RP800-20

PEI RP800-20

$197.00 $395.00

PDA TR 13-2

PDA TR 13-2

$162.00 $325.00